CME Group
CME
$269.80
+0.97%
CME Group Inc. operates the world's leading derivatives marketplace, offering a diverse range of futures and options across interest rates, equity indexes, foreign exchange, energy, agriculture, and metals. As a dominant exchange operator, it holds a near-monopoly in U.S. listed derivatives and benefits from its exclusive licensing of S&P and Dow Jones index futures, alongside a 27% stake in S&P Dow Jones Indices. The current investor narrative centers on how the Federal Reserve's hawkish pivot—with rising rate-hike probabilities and persistent inflation—will impact trading volumes and revenue growth, while the stock's recent volatility reflects broader market concerns about higher-for-longer rates and their effect on financial markets.…
CME
CME Group
$269.80
Related headlines
Investment Opinion: Should I buy CME Today?
Rating: Hold. CME is a high-quality company with strong fundamentals, but the current valuation and macro uncertainties warrant a cautious stance. The analyst consensus is Buy with an average target of $283.93, implying ~7.4% upside, which is modest. The thesis is that CME will benefit from sustained volatility and rate hikes, but the stock's underperformance and high payout ratio limit near-term upside.
Sign up to view all
CME 12-Month Price Forecast
The AI assessment is neutral with medium confidence. CME's fundamentals are strong, but the stock's performance is heavily dependent on Fed policy and market volatility. The recent revenue acceleration is encouraging, but the high payout ratio and premium valuation limit upside. The stance would upgrade to bullish if revenue growth sustains above 15% and the Fed maintains a hawkish stance, or if the stock pulls back to below $240. It would downgrade to bearish if revenue growth falls below 5% or if the Fed signals a dovish pivot, which could compress multiples and reduce trading volumes.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $284.13 and implied upside of +5.3% versus the current price.
Average Target
$284.13
0 analysts
Implied Upside
+5.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$230 - $330
Analyst target range
The target price range spans from $230.00 to $330.00, with the low target suggesting a potential downside of 13.0% and the high target implying an upside of 24.8%. The wide spread of $100 between the low and high targets indicates significant uncertainty about CME's future performance, likely due to varying views on the impact of Fed policy on trading volumes. The high target likely assumes sustained revenue growth and margin expansion, while the low target may price in a recession-driven decline in trading activity. Recent upgrades, such as Keefe, Bruyette & Woods moving to Outperform, signal growing confidence, but the overall range highlights the market's divided expectations.
Bulls vs Bears: CME Investment Factors
CME presents a mixed picture: strong fundamentals with accelerating revenue growth, high margins, and a reasonable forward PE, but offset by significant underperformance, high payout ratio, and sensitivity to Fed policy. The bull case is supported by the acceleration in revenue and analyst optimism, while the bear case is driven by valuation concerns and the risk of a Fed pivot. Currently, the bull case has slightly stronger evidence given the recent revenue acceleration and low beta, but the key tension is whether the Fed's hawkish stance will sustain or reverse. If the Fed hikes as expected, CME could benefit from increased volatility and trading volumes; if it pivots to cuts, the stock may face headwinds. The outcome of this policy path is the single most important factor for the investment thesis.
Bullish
- Revenue growth accelerating: Q1 2026 revenue of $1.88B grew 14.5% YoY, up from 4.2% in Q4 2025, driven by strong clearing and transaction fees. This acceleration reflects heightened market volatility and increased trading activity, positioning CME well in a rising rate environment.
- High margins and profitability: Gross margin is 88.1% and operating margin is 64.9%, with net margin at 62.0%. These exceptional margins provide a strong competitive moat and robust cash generation, supporting continued investment and shareholder returns.
- Attractive valuation with growth: Forward PE of 20.44x is reasonable given expected EPS growth of ~19.5% (PEG 1.59x). This suggests the market is pricing in solid earnings expansion, yet the stock trades below its historical average, offering potential upside.
- Analyst consensus is Buy: With a mean recommendation of 2.44 (Buy) and an average target price of $283.93, analysts see ~7.4% upside from the current price of $264.32. Recent upgrades, such as KBW to Outperform, signal growing confidence.
Bearish
- Underperformance vs. market: CME has declined 6.05% over the past year while the S&P 500 gained 21.46%, underperforming by 27.5 percentage points. This persistent weakness reflects investor concerns about the impact of Fed policy on trading volumes.
- High payout ratio limits growth: With a payout ratio of 97.2%, CME returns nearly all earnings to shareholders, leaving little room for reinvestment or dividend growth. This could constrain future earnings growth and make the stock less attractive to growth investors.
- Valuation premium to peers: PS ratio of 15.06x and EV/EBITDA of 17.05x are at a premium to the broader financial sector. If growth decelerates, the stock could face multiple compression, leading to downside.
- Dependence on Fed policy: The narrative is heavily tied to Fed rate hikes. If the Fed pivots to cuts or signals a pause, trading volumes in interest rate products could decline, directly impacting revenue. Recent news highlights a 73% chance of a September hike, but uncertainty remains.
CME Technical Analysis
CME's price trend over the past year has been predominantly downward, with the stock declining 6.05% over the last 12 months, underperforming the S&P 500's 21.46% gain. Currently trading at $264.32, the stock sits at 41.6% of its 52-week range (between $218.31 and $329.16), indicating it is closer to the lower end of its yearly band. This positioning suggests the stock is in a recovery phase after a significant drawdown, but it remains well below its highs, reflecting persistent bearish sentiment and a potential value opportunity if fundamentals stabilize.
Beta
0.27
0.27x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$218-$329
Price range past year
Annual Return
-1.8%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | +10.0% | +2.9% |
| 3m | -9.7% | +5.0% |
| 6m | -11.0% | +13.9% |
| 1y | -1.8% | +20.4% |
| ytd | +0.0% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
CME's revenue trajectory is robust, with Q1 2026 revenue of $1.88 billion, up 14.5% year-over-year from $1.64 billion in Q1 2025. This marks an acceleration from the 4.2% growth seen in Q4 2025, driven by strong clearing and transaction fees of $1.54 billion, which constitute 82% of total revenue. The multi-quarter trend shows sequential improvement from $1.54 billion in Q3 2025 to $1.88 billion in Q1 2026, indicating accelerating growth. This growth is likely fueled by heightened market volatility and increased trading activity in interest rate and equity index products, positioning CME well in a rising rate environment.
Quarterly Revenue
$1.9B
2026-03
Revenue YoY Growth
+14.5%
YoY Comparison
Gross Margin
88.1%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Given CME's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 24.43x, while the forward PE is 20.44x, implying the market expects earnings growth of approximately 19.5% over the next year. This gap suggests optimism about future earnings expansion, likely driven by continued revenue growth and operational leverage. The PEG ratio of 1.59x indicates that the stock is reasonably priced relative to its expected growth rate, though not deeply undervalued.
PE
24.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CME's financial health is robust, but there are risks. The company has a low debt-to-equity ratio of 0.13, indicating conservative leverage, and a current ratio of 92.97, showing ample liquidity. However, the payout ratio of 97.2% means that nearly all earnings are distributed as dividends, leaving little retained earnings for growth or cushioning against downturns. Revenue concentration in transaction fees (82% of total) exposes CME to volume fluctuations; a decline in trading activity could significantly impact earnings. Additionally, the forward PE of 20.44x implies high market expectations; if growth decelerates, the stock could face de-rating.
FAQ
The key risks of holding CME include: 1) Financial risk: The high payout ratio of 97.2% leaves little room for reinvestment, and a decline in earnings could force dividend cuts. 2) Market risk: The stock is sensitive to Fed policy; a dovish pivot could reduce trading volumes and hurt revenue. 3) Competitive risk: While CME has a near-monopoly, new entrants or regulatory changes could erode its market share. 4) Macro risk: Economic recession could reduce derivatives demand, as seen in the -33% max drawdown over the past year. The most severe risk is a prolonged bear market, which could push the stock to $218.31, a -17.4% decline from current levels.
The 12-month forecast for CME is moderately bullish. The base case scenario, with a 50% probability, expects the stock to trade in the $270-$300 range, aligning with the average analyst target of $283.93. The bull case, with a 30% probability, sees the stock reaching $300-$330 if revenue growth accelerates and the Fed remains hawkish. The bear case, with a 20% probability, could see the stock fall to $218-$240 if the Fed pivots to cuts and volumes decline. The most likely outcome is the base case, assuming the Fed maintains a hawkish stance and trading volumes grow moderately. Investors should monitor Fed policy and quarterly earnings for confirmation.
CME is fairly valued relative to its growth prospects. The forward PE of 20.44x is reasonable given expected EPS growth of ~19.5%, resulting in a PEG ratio of 1.59x, which is slightly above the fair value threshold of 1.0. The PS ratio of 15.06x and EV/EBITDA of 17.05x are at a premium to the broader financial sector, indicating that the market is paying a premium for CME's high margins and dominant position. Compared to its own history, the stock is trading below its 52-week high of $329.16, suggesting a discount. Overall, the valuation implies that the market expects continued growth, but not at an excessive pace. It is neither deeply undervalued nor overvalued.
CME is a good stock to buy for investors seeking a defensive, income-generating position with moderate growth potential. The stock offers a 4.0% dividend yield and has a low beta of 0.27, providing stability in volatile markets. Analysts have a Buy rating with an average target of $283.93, implying ~7.4% upside from the current price of $264.32. However, the stock has underperformed the market over the past year, and its high payout ratio limits growth. It is a good buy for long-term investors who believe in the durability of derivatives trading and want to hedge against market volatility, but it may not be suitable for aggressive growth investors.
CME is more suitable for long-term investment due to its defensive characteristics and stable cash flows. With a beta of 0.27, it offers low volatility, making it a good core holding for income-focused portfolios. The stock pays a 4.0% dividend yield, which provides a steady income stream. However, its growth is moderate, and it may not offer the high returns that aggressive short-term traders seek. For short-term traders, CME's price movements are influenced by Fed policy and market volatility, which can create trading opportunities, but the low beta limits upside. A minimum holding period of 3-5 years is recommended to ride out macro cycles and benefit from dividend compounding.